Skip to main content

Search

Reset all filters
131 Result(s)
Sort by

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

New clinical trial data published in the New England Journal of Medicine, showed that spesolimab, a novel IL-36R antibody treatment, was effective in rapidly treating adult patients with generalized pustular psoriasis (GPP) experiencing a flare.
Life forward - Boehringer Ingelheim unveils its evolved company brand

Life forward - Boehringer Ingelheim unveils its evolved company brand

Ingelheim, Germany, 30/10/2023 | Boehringer Ingelheim, a leading research-driven biopharmaceutical company, on Monday presented a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners
Business Ethics

Business Ethics

The ethical principles that have guided Boehringer Ingelheim for 130 years created a culture of corporate and social responsibility and commitment.